AstraZeneca and Ionis see pivotal trial miss for ATTR-CM drug Wainua
AstraZeneca announced that its experimental therapy Wainua, developed with Ionis, failed to meet primary endpoints in a pivotal study for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
The trial showed no statistically significant reduction in cardiovascular death or related clinical events compared with placebo.
The news sent AstraZeneca's U.S.-listed shares down about 8% in pre-market trading and its London shares down roughly 9%, while Ionis stock fell about 12%.
The setback underscores the competitive landscape for treatments targeting ATTR-CM and may delay the companies' plans to bring a therapy to market.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug”
read at STAT ↗
comments(0)
5-min edit window · permanent after that